Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ATS bankruptcy

This article was originally published in The Gray Sheet

Executive Summary

Smith & Nephew will gain full control of the Dermagraft tissue-engineered dermal replacement product joint venture with Advanced Tissue Sciences via a proposed purchase of ATS' stake for $12 mil. ATS, which filed for Chapter 11 protection Oct. 10 in southern California federal bankruptcy court, expects to be advanced up to $5 mil. of the purchase price to continue operations until the sale is approved by the court. In addition to Dermagraft for diabetic foot ulcers, the deal includes TransCyte temporary skin cover for serious burns; combined sales are expected to reach $8 mil. this year, S&N says. Upon completion of the deal, S&N will become a contract manufacturer for non-wound care products retained by ATS. The companies will dissolve their NeoCyte human cartilage development joint venture...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT017285

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel